Table 2. Epidemiological, clinical, biochemical, and histological parameters of the seven patients with hepatocellular carcinoma and Schistosoma mansoni infection.
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|---|
| Gender | M | M | M | M | M | F | M |
| Age (years) | 65 | 79 | 67 | 61 | 51 | 64 | 48 |
| Epidemiology | Y | Y | Y | Y | Y | Y | Y |
| UGB | N | Y | N | Y | N | Y | Y |
| Splenectomy/year | Y/NA | N | Y/1960 | Y/1974 | N | N | Y/1979 |
| PVT | N | N | Y | Y | Y | Y | Y |
| HBV contact | N | Y | Y | Y | N | Y | N |
| HCC histology | MD | N | MD | N | N | N | MD |
| AFP (ng/mL) | 4.0 | 2.9 | 6.8 | 4692.0 | 2563.0 | 10.5 | 26.0 |
| Nodules (number) | 1 | 2 | 1 | 2 | 1 | 1 | 5 |
| HCC size (mm) | 70 | 110 | 57 | 40 | 72 | 40 | 49 |
| Metastases | N | N | N | N | N | N | N |
| Vascular invasion | N | Y | N | N | N | N | N |
| ECOG PS | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| BCLC | B | C | B | B | B | A | B |
| HCC Therapy | TACE | Palliative | Sorafenib | Sorafenib | TACE | TACE | Sorafenib |
M, male; F, female; Y, yes; N, no; NA, not available; UGB, upper gastrointestinal bleeding; TPV, thrombosis of portal vein; HBV contact, HBsAg negative, total anti-HBc positive, anti-HBs positive; HCC, hepatocellular carcinoma; MD, moderately differentiated; AFP, alpha-fetoprotein; ECOG PST, Eastern Cooperative Oncology Group performance status; BCLC, Barcelona Clinic Liver Cancer criteria; TACE, transcatheter arterial chemoembolization.